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Abstract
Background: Malaria immunity is commonly believed to wane in the absence of Plasmodium falciparum exposure,
based on limited epidemiological data and short-lived antibody responses in some longitudinal studies in endemic
areas.
Methods: A cross-sectional study was conducted among sub-Saharan African adults residing in Spain for 1 up to 38
years (immigrants) with clinical malaria (n=55) or without malaria (n=37), naïve adults (travelers) with a first clinical
malaria episode (n=20) and life-long malaria exposed adults from Mozambique (semi-immune adults) without malaria
(n=27) or with clinical malaria (n=50). Blood samples were collected and IgG levels against the erythrocytic antigens
AMA-1 and MSP-142 (3D7 and FVO strains), EBA-175 and DBL-α were determined by Luminex. IgG levels against
antigens on the surface of infected erythrocytes (IEs) were measured by flow cytometry.
Results: Immigrants without malaria had lower IgG levels than healthy semi-immune adults regardless of the antigen
tested (P≤0.026), but no correlation was found between IgG levels and time since migration. Upon reinfection,
immigrants with malaria had higher levels of IgG against all antigens than immigrants without malaria. However, the
magnitude of the response compared to semi-immune adults with malaria depended on the antigen tested. Thus,
immigrants had higher IgG levels against AMA-1 and MSP-142 (P≤0.015), similar levels against EBA-175 and DBL-α,
and lower levels against IEs (P≤0.016). Immigrants had higher IgG levels against all antigens tested compared to
travelers (P≤0.001), both with malaria.
Conclusions: Upon cessation of malaria exposure, IgG responses to malaria-specific antigens were maintained to a
large extent, although the conservation and the magnitude of the recall response depended on the nature of the
antigen. Studies on immigrant populations can shed light on the factors that determine the duration of malaria
specific antibody responses and its effect on protection, with important implications for future vaccine design and
public health control measures.
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Introduction
Maintenance of long-term memory responses is critical for
achieving protective immunity against many pathogens. The
understanding of differential immuno-reactivity to malaria and
maintenance of these immune responses is fundamental for
the development and design of immunogenic strategies for
disease control and eradication. In malaria endemic areas,
immunity is acquired gradually with age and continuous
exposure, first to severe disease and ultimately to clinical
malaria and high parasitemia [1]. Nevertheless, it is thought
that upon cessation of exposure to Plasmodium falciparum
infection immunity wanes rapidly, and this is in contrast with the
long-term antibody-mediated immunity that follows one or few
exposures to antigens from other infectious microbes [2].
The control of P. falciparum infections is complex, and
requires the combined action of antibodies (Ab) and cell-
mediated immune responses against both pre-erythrocytic and
blood stages; and these two effector mechanisms are required
for both anti-parasitic as well as clinical immunity [3,4]. The
relevance of Ab responses in malaria protection was
established several decades ago by immunoglobulin G (IgG)
passive transfer experiments [5,6], and different mechanisms
of immunity have been proposed. Potential Ab effector actions
include: blockade of hepatocyte invasion by sporozoites and
red blood cell invasion by merozoites; Ab-dependent cellular
killing through interaction of target-bound Ab with certain Fc
receptors from cell surfaces; opsonization of infected
erythrocytes (IE) inducing phagocytic clearance; and
neutralization of the parasite glycosylphosphatidylinositol,
inhibiting the induction of the inflammatory cytokine cascade
[3]. P. falciparum antigens targeted by naturally acquired IgG
associated with immunity include the merozoite proteins: apical
membrane antigen 1 (AMA-1), the 42-kDa fragment from the C
terminus of merozoite surface protein 1 (MSP-142), and the 175
kDa erythrocyte binding antigen (EBA-175), all three involved
in erythrocyte invasion [7–11]. In addition, variant surface
antigens (VSA) expressed on IE membranes are also targets of
naturally acquired Ab responses associated with immunity [12].
The P. falciparum erythrocyte membrane protein 1 (PfEMP-1)
is the major antigen of this VSA family, containing several
domains that mediate cytoadherence to host cells, like the
Duffy binding-like alpha (DBL-α) domain that is involved in
rosetting [13].
Despite the common perception that immune memory to
malaria is short-lived in the absence of exposure, most clinical
evidence suggests that immunity may last for long periods of
time. Immigrants maintain some immunity to clinical malaria,
and have milder episodes than naïve adults with a malaria
primary infection [14–21]. Also in areas of low or unstable
malaria transmission such as Madagascar, adults previously
exposed to malaria, even several decades before, were
protected against clinical disease during malaria epidemics
[22–24].
However, data on the longevity of protective immune
responses are scarce. Ab responses to malarial antigens are
often thought to be short-lived [25–30], although this has
mostly been reported in children in areas where malaria is
endemic [27–31]. On the contrary, in adults, long-lived IgG
responses have been detected [32–35]. It appears that
frequent reinfection is required to maintain high levels of
circulating Ab, thus in highly endemic areas Ab levels are
stable [36,37], but in low or unstable transmission areas Ab
levels diminish quickly after an infection [28,38], showing
seasonal variation [26,27,39–41]. Conversely, memory B cells
(MBC) can persist with reduced transmission [42–45].
However, a study reported the presence of Ab, but only very
low frequencies of malaria-specific MBC in children, suggesting
a low induction of malaria-specific circulating MBC as a reason
for short-lived anti-malarial Ab responses [46].
The aim of this study was to measure P. falciparum-specific
Ab responses as indicative of loss or maintenance of immunity
in immigrants who have not been exposed to malaria for long
periods of time. We compared IgG levels against a panel of
blood stage antigens thought to be involved in malaria
immunity between previously exposed immigrants,
continuously exposed adults and naïve travelers, with or




Written informed consent was obtained from participants
before sample collection. Approval for the protocols was
obtained from the Hospital Clínic of Barcelona Ethics Review
Committee and the National Mozambican Ethics Review
Committee. Parasitemic individuals were treated according to
standard national guidelines at the time of the studies.
Study design, subjects and sample collection
Three groups of participants were recruited for this study: (i)
sub-Saharan African adults originally from malaria endemic
areas residing in Spain (immigrants) without clinical malaria
(n=37) or with clinical malaria (n=55) upon return from travel;
(ii) adults from a sub-Saharan Africa endemic area with life-
long exposure to P. falciparum infection (semi-immune adults),
with (n=50) or without clinical malaria (n=27); and (iii) naïve
adults from a non-endemic area returning from a sub-Saharan
Africa malaria endemic region with a first malaria episode
(travelers, n=20).
Immigrants were recruited at the Tropical Medicine Units of
Hospital Clínic de Barcelona (Barcelona, Spain), Hospital
Arnau de Vilanova (Lleida, Spain) and Hospital Santa Caterina
de Salt (Girona, Spain) between 2005 and 2009. Travelers
were recruited at the Tropical Medicine Unit of the Hospital
Clínic de Barcelona (Barcelona, Spain) [47]. Fifty-five
immigrants and 20 travelers were diagnosed with P. falciparum
clinical malaria after traveling to an African country. Clinical
malaria was defined as the presence of asexual P. falciparum
parasites on Giemsa-stained blood smears detected by light
microscopy, together with fever. P. falciparum parasitemia in
blood was measured as the percentage of parasitized red
blood cells. Blood samples from acute malaria episodes (day 0)
and at convalescence after malaria treatment (day 7) were
collected by venipuncture into vacutainers without
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anticoagulant for serum cryopreservation at -80° C. In addition,
blood samples from 37 immigrants visiting the Tropical
Medicine Units without malaria were also collected. These
immigrants were healthy companions or those presenting with
non-malaria diseases. Most of them had a febrile syndrome or
traveler diarrhea but the following conditions were also
diagnosed: giardiasis, katayama syndrome, mononucleosis
syndrome EBV, pneumonia, pruritus eczema, anxiety disorder,
appendicitis, dermatitis, toxic syndrome, viral infection,
ketoacidosis, diabetes, headache, spontaneous abortion,
bacterial lung abscess and HIV infection. Clinical and
demographical data were recorded in standardized
questionnaires. Data on Ab levels from travelers have been
previously published [47], but are re-analysed here for
comparison to the immigrant group.
Semi-immune adults were from Manhiça District in
Mozambique, where malaria transmission is perennial, with
some seasonality and moderate intensity. Fifty semi-immune
adults with P. falciparum clinical malaria were recruited at the
Manhiça District Hospital in the context of a hospital-based
study conducted at the Centro de Investigação em Saúde de
Manhiça in 2006 [13]. Clinical malaria was defined as the
presence of asexual P. falciparum parasites on blood smears,
together with fever. Blood films were Giemsa-stained, and
examined using a light microscope and parasite density in
blood was measured as parasites/µL. Additionally, 27 healthy
semi-immune adults were recruited in a cross-sectional study
in the Manhiça District between 2005 and 2006. They were
adults who had not lived in a city and were not parasitemic by
microscopy at the moment of collecting the blood samples.
Blood samples were collected by venipuncture into heparinized
tubes, and plasma samples were cryopreserved at -80° C.
Recombinant proteins
AMA-1 from the 3D7 strain [48], the receptor-binding region
F2 of EBA-175 from the CAMP strain [49] and the DBL-α
domain of a PfEMP-1 involved in rosetting [13] were produced
as recombinant proteins at ICGEB. AMA-1 from FVO strain,
and MSP-142 from 3D7 and FVO strains [50,51] were produced
as recombinant proteins at WRAIR.
Antibody levels to recombinant proteins
IgG responses to P. falciparum antigens were determined
using Luminex xMAPTM (Luminex Corp., Austin, Texas, USA)
and the Bio-Plex 100 platform (Bio-Rad, Hercules, California,
USA) as previously described [47,52]. A pool of plasma
samples from hyper-immune Mozambican adult volunteers
(n=33), and 4 plasma samples from non-exposed European
adults (n=42) were added in duplicates to each plate as
positive and negative controls, respectively. In addition, curves
of a pool of plasma samples from hyper-immune adults were
added in each experiment (Figure S1). Study samples were
tested in duplicates at the dilutions 1/1,000 and 1/30,000, but
only the dilution 1/1,000 was chosen for the statistical analyses
because of a wider quantitative dynamic range. In some wells
no serum/plasma was added as a control of background.
Plates were read using Bio-Plex Manager version 4.0, and at
least 100 microspheres per analyte were acquired per sample.
Median fluorescent intensity with background fluorescence
subtracted was exported, and arbitrary units (AU) concentration
for each Ab was calculated by dividing the median fluorescent
intensity of each sample by the median fluorescent intensity of
the positive control run in each plate.
Antibodies to IEs surface antigens
Two laboratory clones (CS2, R29), three isolates collected
from travelers to endemic regions (IETrav1, IETrav2, IETrav3), two
pediatric isolates from Mozambican children, one with
uncomplicated malaria (IECh1) and another with severe malaria
(IECh2), and one isolate from a pregnant Mozambican woman
(IEWoman), each of whom had the O blood group, were tested for
recognition by IgG using flow cytometry as previously
described [47]. Cryopreserved ring-stage parasites were
thawed in a sorbitol gradient and grown to late trophozoites.
Study samples were tested blindly in a single assay against
each parasite. A pool of plasma samples from hyper-immune
Mozambican adults (n=11) and 10 samples from non-exposed
European adults were included as positive and negative
controls, respectively. Data from 1,000 positive events was
acquired with a Becton-Dickinson (BD) FACSCalibur flow
cytometer. Reactivity against IE surface antigens was
expressed as the difference between the geometric mean
fluorescent intensity (MFI) of IEs and the MFI of uninfected
erythrocytes. Representative flow cytometry data are showed
in Figure S2.
Statistical methods
Recognition of recombinant proteins by Ab was considered
positive if AU values were above the mean of the negative
controls plus 2 standard deviations. Threshold values for
seroprevalence were: 238.02 AU for AMA-1 3D7; 1134.73 AU
for AMA-1 FVO; 921.18 AU for MSP-142 3D7; 638.33 AU for
MSP-142 FVO; 3110.36 AU for EBA-175; 1572.55 AU for DBL-
α. Recognition of parasites by Ab was considered positive if
MFI values were above the mean of the negative controls plus
3 standard deviations. Threshold values for seroprevalence
were: 36.88 MFI for IETrav1, 38.55 MFI for IETrav2, 24.75 MFI
IETrav3, 14.23 MFI for CS2, 19.92 MFI for R29, 8.69 MFI for ECh1,
1.98 MFI for IECh2, and 5.54 MFI for IEWoman. Comparisons
between groups for categorical variables were done using χ2
test or Fisher’s exact test. Continuous variables were analyzed
using the non-parametric Kruskal Wallis test or the Wilcoxon
Rank Sum test. Correlations between IgG levels and years
since migration were assessed by Spearman’s rank coefficient.
All p-values were two-sided and considered statistically
significant when < 0.05. All data collected were analyzed using
Stata version 11.0 (Stata Corporation, College Station, Texas,
USA).
Results
Characteristics of the study participants
The characteristics of study participants are summarized in
Table 1. Immigrants with malaria were originally from
Cameroon (n=3, 5.5%), Ghana (n=8, 14.6%), Guinea-Conakry
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(n=4, 7.3%), Equatorial Guinea (n=12, 21.8%), Gambia (n=8,
14.6%), Mali (n= 4, 7.3%), Mauritania (n=1, 1.8%),
Mozambique (n=1, 1.8%), Nigeria (n=6, 10.9%) and Senegal
(n=7, 12.7%). Immigrants without malaria were from Benin
(n=1, 2.7%), Burkina Faso (n=2, 5.41%), Cameroon (n=3,
8.11%), Guinea-Conakry (n=3, 8.11%), Equatorial Guinea
(n=3, 8.11%), Gambia (n=3, 8.11%), Kenya (n=1, 2.7%), Mali
(n=9, 24.32%), Mauritania (n=1, 2.7%), Mozambique (n=1,
2.7%), Nigeria (n=3, 8.11%), Senegal (n=5, 13.61%) and
Sudan (n=1, 2.7%). Most of the semi-immune adults without
malaria were males, whereas there were more females among
the semi-immune adults with malaria than in the other groups
(P=0.001). Visiting countries were very heterogeneous among
immigrants and travelers. Immigrants were those returning
from visiting their countries of origin. Travelers came from
Burkina Faso & Mali & Senegal (n=1, 5.0%), Burkina Faso
(n=3, 15.0%), Burkina Faso & Mali & Ghana & Togo (n=1,
5.0%), Ivory Coast (n=1, 5.0%), Guinea-Conakry (n=1, 5.0%),
Equatorial Guinea (n=3, 15.0%), Gambia & Senegal (n=1,
5.0%), Madagascar (n=1, 5.0%), Mali (n=1, 5.0%),
Mozambique (n=2, 10.0%), Mozambique & South Africa (n=1,
5.0%), Senegal (n=3, 15.0%) and Sierra Leone & Senegal
(n=1, 5.0%). Immigrants with malaria had lived a median of 7
years in Spain, whereas immigrants without malaria had lived a
median of 5 years (P= 0.0362, Table 1). However, 10% of
immigrants with malaria were returning from their first trip to
their original country, 21% had previously returned 1 to 2 times,
50% had returned 3 to 4 times and 19% had returned more
than 5 times. Forty-seven percent of immigrants without
malaria had never returned to their original country, 15% had
returned 1 to 2 times, 12% had returned 3 to 4 times and 27%
had returned more than 5 times. No significant differences
were detected in parasitemia between immigrants and travelers
(P=0.0890, Table 1).
Antibodies in immigrants without malaria
IgG levels and seroprevalence against erythrocytic antigens
associated with immunity, and against a set of IE of different
origins, were determined in immigrants and compared to semi-
immune adults from Mozambique to assess if the cessation of
exposure had an effect on basal Ab levels. IgG levels (Figure
1) and seroprevalences (Table 2) against all recombinant
proteins tested were lower in non-infected immigrants
compared to healthy semi-immune adults, with the exception of
AMA-1 3D7 that the difference between groups was not
statistically significant, and the seroprevalence of DBL-α that
was similar in both groups.
Antibodies in immigrants upon malaria reinfection
Ab levels and prevalence were determined in immigrants and
semi-immune adults, both with an acute episode of clinical
malaria (Figure 2, Table 3). Immigrants showed higher Ab
levels against the merozoite antigens AMA-1 and MSP-142
(Figure 2A). There were no differences in Ab responses to
EBA-175 and DBL-α. However, immigrants had significantly
lower levels of Ab against all IEs compared to semi-immune
adults (Figure 2B). No differences were detected in
seroprevalence between immigrants and semi-immune adults
with the exception of IECh1, which was higher in the later (Table
3).
Next, Ab responses in immigrants were compared with Ab
responses in travelers during an acute malaria episode and in
convalescence (Figure 3, Table 3). Overall, infected immigrants
had higher Ab levels and seroprevalences against erythrocytic
antigens (Figure 3A, Table 3) and IEs (Figure 3B, Table 3)
compared to travelers.
Figure 1.  IgG antibody responses to merozoite antigens in immigrants (Immigr) and semi-immune adults (S-Immune)
without malaria.  Data are presented as boxplots that illustrate the medians and the 25th and 75th quartiles, and the whiskers
represent the 10% and 90% percentiles. Outliers are marked with circles. P-values were calculated using the Wilcoxon Rank Sum
test. Cutoff values for seroprevalences were 238.02 AU for AMA-1 3D7; 1134.73 AU for AMA-1 FVO; 921.18 AU for MSP-142 3D7;
638.33 AU for MSP-142 FVO; 3110.36 AU for EBA-175; 1572.55 AU for DBL-α.
doi: 10.1371/journal.pone.0073624.g001
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Table 1. Characteristics of the study participants.
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Day 0 55 37 20 50 27












Sexb, n (%)      
Males 40 (73) 23 (62) 15 (75) 28 (56) 26 (96)
Origin area, n (%)      
Europe 0 (0) 0 (0) 17 (85) 0 (0) 0 (0)
Africa 54 (100) 37 (100) 0 (0) 50 (100) 27 (100)









     
0 5 (10) 16 (47) na na na
1-2 11 (21) 5 (15) na na na
3-4 26 (50) 4 (12) na na na
>5 10 (19) 9 (27) na na na
Parasitemia by
microscopy
















Abbreviations: IQR, interquartile range; nd, not determined; na, not applicable
a. P=0.0515 Kruskal Wallis test. Data missing from 2 semi-immune adults without
malaria
b. P=0.001 χ2
c. P= 0.0362 Wilcoxon Rank Sum test. Data available from 52 immigrants with
malaria and 34 without malaria.
d. P=0.0890 Wilcoxon Rank Sum test.
Table 2. IgG seroprevalence in immigrants and semi-
immune adults without malaria.
 Immigrants (n=37) Semi-Immune (n=27)  
 n % n % P-value*
AMA-1 3D7 35 95 27 100 0.504
AMA-1 FVO 30 81 27 100 0.018
MSP-142 3D7 31 84 27 100 0.035
MSP-142 FVO 30 81 27 100 0.018
EBA-175 12 32 17 63 0.022
DBL-α 7 19 12 44 0.051
*. Fisher’s exact test
Effect of time since cessation of exposure on antibody
levels
The effect of time since immigration on Ab levels in
individuals without malaria or with a clinical malaria episode
was assessed. None of the Ab against the antigens tested
showed any correlation with the time since migration (data not
shown) in immigrants with malaria or without malaria. Similarly,
no significant differences were found in IgG levels or
seroprevalences between individuals that had migrated from
their malaria endemic country of origin 5 or fewer years ago,
and those that had migrated more than 5 years ago, without
malaria (Table S1) or with clinical malaria (Table S2).
Discussion
In this study we found that after long periods without
continuous malaria exposure, immigrants from endemic areas
without malaria still presented seropositivities of 32% to 98%
for erythrocytic antigens considered as leading vaccine
candidates, and immigrants with clinical malaria had similar
seroprevalences than semi-immune adults also with a clinical
episode However, immigrants without malaria had lower levels
of IgGs to all antigens tested compared to healthy adults with
continuous life-long exposure to malaria. Although this may
suggest that there is some loss of immunity, in this cohort we
did not observe an association between time since migration
and Ab levels, which may indicate that IgG are longer-lived
than usually perceived, at least in adults. In addition, we cannot
discard that the healthy adults recruited in Mozambique may
have been recently exposed.
Immigrants with clinical malaria had higher IgG levels
compared to immigrants without malaria and compared to
naïve adults with a primary infection. This may indicate that
even at day of presentation to the clinics with malaria, there is
boosting of Ab against a wide repertoire of antigens. Rapid
boosting of Ab responses to various P. falciparum antigens has
been reported after re-exposure to malaria following prolonged
periods of either sustained control or low transmission, in both
children and adults [35,40], suggesting that there is
maintenance of immune memory and the capacity to respond
quickly to reinfection. Nevertheless, previous exposure could
account for part of this difference between the two groups of
immigrants. Migrants who contracted malaria upon return to
their countries of origin could have been historically more
exposed than migrants without clinical malaria (i.e. because
there is higher malaria transmission intensity in those areas).
However, we think this is unlikely since the subjects were form
highly diverse areas. In addition, differences with the group of
travelers could be due to different times of presentation to
clinical attention: partially immune immigrants could have a
smoldering blood stage infection for weeks whereas travelers
would require clinical attention within a few days of the start of
the blood stage infection, before their antibody response
peaked. This, however, argues in favor of our hypothesis that
there is maintenance of immunity.
Interestingly, the magnitude of Ab responses in immigrants
with clinical malaria compared to Mozambican semi-immune
adults with clinical malaria varied according to the type of
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antigen. Three different response patterns could be identified.
First, immigrants had higher levels of IgG against the merozoite
antigens AMA-1 and MSP-142, which are relatively polymorphic/
dimorphic [11,53] and highly immunogenic, although many
studies have associated them with malaria exposure rather
than protection [54–56]. In contrast, both study groups had
similar levels of Ab against EBA-175 and DBL-α. EBA-175 is
more conserved and less immunogenic than AMA-1 and
MSP-142, but more consistently associated with protection from
clinical malaria [8,54,55] in our previous studies. DBL-α is also
less immunogenic and relatively polymorphic considering that it
is a PfEMP-1 domain, which is a highly diverse protein [13]. In
fact, it is the most conserved PfEMP-1 domain, probably due to
its function in mediating rosetting, and Ab against it have been
associated with protection against malaria severity [57]. Finally,
immigrants had lower levels of IgG against VSA on IEs that are
the most polymorphic and poorly immunogenic upon initial
exposures to parasite infections [58]. Therefore, these results
together with our previous data on Ab responses to these
antigens in young Mozambican children [8,52,58] suggest that,
after extended periods in the absence of P. falciparum
exposure, the magnitude of Ab recall responses upon
reinfection depend on the nature of the antigen, as does the
pattern of acquisition of such responses upon initial parasite
exposure. Nevertheless, genetic and/or environmental
differences between migrants who were originally from very
diverse countries, and semi-immune adults who were from a
unique African endemic area, could also account for some of
the differences observed between these groups.
The finding that clinical malaria in immigrants induced higher
Ab levels for the more immunogenic antigens may be
attributable to a B cell response inclined toward merozoite
antigens instead of a broad B cell response against a wider
repertoire of different antigens. In contrast, the semi-immune
group had greater Ab reactivity against multiple variants of IE
antigens, indicating that the response under continuous
Figure 2.  IgG antibody responses to merozoite antigens (A) and P. falciparum Infected Erythrocytes (B) in immigrants
(Immigr) and Semi-Immune adults (S-Imm) with clinical malaria.  Data are presented as boxplots that illustrate the medians and
the 25th and 75th quartiles, and the whiskers represent the 10% and 90% percentiles. Outliers are marked with circles. P-values were
calculated using the Wilcoxon Rank Sum test. Cutoff values for seroprevalences were 238.02 AU for AMA-1 3D7, 1134.73 AU for
AMA-1 FVO, 921.18 AU for MSP-142 3D7, 638.33 AU for MSP-142 FVO,3110.36 AU for EBA-175, 1572.55 AU for DBL-α, 36.88 MFI
for IETrav1, 38.55 MFI for IETrav2, 24.75 MFI IETrav3, 14.23 MFI for CS2, 19.92 MFI for R29, 8.69 MFI for ECh1, 1.98 MFI for IECh2, and
5.54 MFI for IEWoman.
doi: 10.1371/journal.pone.0073624.g002
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exposure may be directed toward control of parasite variants
[12]. Immunity to IEs is slowly acquired in infancy due to the
high polymorphism of parasite antigens expressed on the
surface of the erythrocytes, resulting in the need of cumulative
exposures to acquire an Ab repertoire able to recognize
antigenically distinct PfEMP-1 molecules [59,60]. The
interruption of malaria exposure in immigrants, and therefore
the interruption of acquisition of immunity to VSA, may explain
why they have lower Ab levels and why they do not respond to
the same extent as continuously exposed semi-immune adults
upon re-exposure against these antigens. However, since we
do not have data on their antibody levels at the time of
migration we cannot discard that the lower levels are due to a
loss of immunity.
In contrast, the maintenance of Ab responses against DBL-α
and EBA-175, which have been shown to be important in
protection from clinical and severe malaria, could represent
evidence that immunity to the most severe manifestations of
clinical malaria is largely maintained, as clinical data appear to
show [14–20]. Data comparing IgG levels in immigrants with
malaria against IgG levels in naïve adults with a primary
infection represent further evidence of maintenance of
immunity, as immigrants had higher IgG levels against all
antigens and IEs. This is consistent with clinical observations
that migrants rarely get severe/deadly malaria compared to
travelers [14–21].
Table 3. IgG seroprevalence in immigrants and semi-
immune adults with a clinical malaria episode, and naïve

















54 98 48 96 9 45 0.604 <0.001
AMA-1
FVO
54 98 47 94 6 30 0.345 <0.001
MSP-142
3D7
55 100 47 94 10 50 0.105 <0.001
MSP-142
FVO
54 98 46 92 8 40 0.189 <0.001
EBA-175 34 62 25 50 0 0 0.243 <0.001
DBL-α 22 40 14 28 3 15 0.222 0.054
IETrav1 51 93 49 98 4 20 0.366 <0.001
IETrav2 52 95 50 100 7 35 0.245 <0.001
IETrav3 49 89 49 98 1 5 0.115 <0.001
CS2 15 27 22 44 0 0 0.102 0.008
R29 50 91 48 96 7 35 0.441 <0.001
IECh1 49 89 50 100 1 5 0.028 <0.001
IEWoman 47 85 47 94 1 5 0.207 <0.001
IECh2 50 91 50 100 2 10 0.058 <0.001
*. Fisher’s exact test
Although our results show that there are P. falciparum-
specific Ab memory responses after long periods without
exposure to malaria, the effect of these responses on immunity
is not clear. We do not know if these Ab responses would lead
to protection from infection or clinical/severe malaria upon
reinfection. However, immigrants returning with clinical malaria
have not been protected from infection or clinical malaria in this
occasion, but this does not imply per se that they have no
immunity to malaria. It could be that the progression of the
disease was different than the naïve or the semi-immune
adults. Unfortunately, we do not have data on the progression
of the disease. In addition, we cannot conclude that they have
lost immunity since even continuously exposed adults may
have clinical malaria, which is what we observed also with the
group of semi-immune adults in Mozambique. We are probably
facing two different layers of immunity, in which the
maintenance of basal levels of Ab is key in the initial control of
a reinfection, whereas the capacity to generate effector
responses (new Ab and MBC) may lead to prevention of
malaria pathogenicity and severity.
Previous findings on long-lived malaria-specific MBC support
maintenance of memory responses. Malaria-specific MBC were
detected in adults from a low endemicity setting in Thailand
and found to persist for more than 7 years without ongoing
exposure [44]. In The Gambia, the median number of malaria-
specific MBC was similar to the median number of diphtheria-
specific MBC, suggesting that the malaria-specific circulating
MBC pool is of similar magnitude to that of other antigens [45].
However, it is not clear whether Ab levels correlate with MBC,
and the maintenance of the plasma cell pool may be
independent of MBC [61]. P. falciparum Ab and MBC have
been shown to correlate when there is recent exposure, but
correlation does not seem to persist after long periods of non-
exposure [32,39,42,45]. The role and contribution of MBC in Ab
levels of a recall response during a malaria infection needs to
be addressed more thoroughly.
While Ab responses to erythrocytic antigens seem to be
maintained to a large extent, cytokine profiling in these same
individuals showed that, upon loss of exposure, control of pro-
inflammatory response and tolerance to P. falciparum may be
reduced [62]. No correlation was found between plasma
cytokine or chemokine concentrations and Ab levels. However,
other Ab responses involved in “anti-disease immunity” or
tolerance [63] may be directly implicated in the cellular immune
response, and may be more short-lived than the Ab responses
measured in this study.
The results of this work highlight the usefulness of migrant
populations’ studies to understand the maintenance of
immunity to malaria and to disentangle determinants and
mediators, allowing the study of memory immune responses
without the interference of natural malaria exposure.
Nevertheless, several limitations were faced. We could not
control for the immune status of the migrants when arriving to
the non-endemic area, or for the number of returns to their
country of origin with possible malaria exposure and boost of
the immune responses. However, none of them had a malaria
episode after their migration and the exposure may have been
minimal due to the few times they returned and the nature of
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these short trips. Longitudinal migrant cohort studies would
resolve the limitations of the present study and would allow for
more precise assessment of long-term immunological
maintenance. Further research into the factors that determine
the duration of specific Ab responses and the underlying
immune mechanisms will be important for vaccine design to
induce levels of immunity that are more protective and
sustained than those attained by current vaccine candidates
[64]. Public health will ultimately benefit from a better
understanding of the mechanisms involved in the maintenance
of immunity upon loss of exposure, since malaria control
strategies leading to diminished malaria transmission may
decrease the population’s immunity with detrimental
consequences in the case of malaria resurgence.
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Figure S1.  Luminex IgG curves for each tested antigen
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(Immigr) and travelers (Trav) with clinical malaria.  IgG levels were determined at the acute episode of malaria (day 0, black
boxes) and at convalescence (day 7, white boxes). Data are presented as boxplots that illustrate the medians and the 25th and 75th
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